AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11682389 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation with BIS target of 80
Number of subjects: 30
Study 9202917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (50%) in oxygen
Number of subjects: 50
Study 9202917 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl with preoxygenation
Number of subjects: 50
Study 7970548 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol and atropine combined
Number of subjects: 0
Study 7970548 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol alone
Number of subjects: 0
Study 3310418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (H.) in combination with systemic or intravesical chemotherapy
Number of subjects: 260
Study 3310418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronidase (H.) with mitomycin C
Number of subjects: 260
Study 3310418 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant intravesical mitomycin C alone
Number of subjects: 260
Study 3310418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical hyaluronidase (H.)
Number of subjects: 260
Study 3310418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (H.) during arterial perfusion in colorectal cancer
Number of subjects: 260
Study 3310418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (H.) with 5‐FU in colorectal cancer stem cell assays
Number of subjects: 260
Study 31899533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab use among oncologists' peers in 2005 to 2006
Number of subjects: 44712
Study 31899533 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities with the highest rates of bevacizumab use in 2005 to 2006
Number of subjects: 44712
Study 30921225 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally robotic right hemicolectomy (TRRH)
Number of subjects: 192
Study 30921225 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted right hemicolectomy (RARH)
Number of subjects: 192
Study 28135023 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs and/or paracetamol
Number of subjects: 482
Study 28135023 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs only
Number of subjects: 482
Study 28135023 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol only
Number of subjects: 482
Study 28135023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NSAIDs and paracetamol
Number of subjects: 482
Study 26249767 — intervention group
Group type: EXPERIMENTAL
Intervention: LEVO 200 µg once-daily
Number of subjects: 78
Study 26249767 — intervention group
Group type: EXPERIMENTAL
Intervention: LEVO 200 µg twice-daily
Number of subjects: 78
Study 26249767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 26249767 — intervention group
Group type: EXPERIMENTAL
Intervention: LEVO 200 µg once-daily vs LEVO 200 µg twice-daily
Number of subjects: 78
Study 24242260 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV stigma reduction intervention
Number of subjects: 507
Study 24242260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 507
Study 21985524 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prisoners
Number of subjects: 425
Study 21985524 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboriginal prisoners
Number of subjects: 425
Study 19857150 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy with low-molecular-weight heparins
Number of subjects: 0
Study 19857150 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE prophylaxis and/or prompt treatment
Number of subjects: 0
Study 19857150 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive VTE management and strategies
Number of subjects: 0
Study 17029611 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan increase (ATI)
Number of subjects: 29
Study 17029611 — intervention group
Group type: COMPARATOR
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 29
Study 15272643 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day (group A)
Number of subjects: 24
Study 15272643 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group B)
Number of subjects: 24
Study 11141646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 11141646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9549924 — intervention group
Group type: COMPARATOR
Intervention: CMV‐IgG 100 mg/kg/week
Number of subjects: 128
Study 9549924 — intervention group
Group type: EXPERIMENTAL
Intervention: HDIgG 400 mg/kg/week
Number of subjects: 128
Study 8172750 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 60
Study 8172750 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 60
Study 8172750 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 8172750 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (pre-existing condition)
Number of subjects: 60
Study 2830688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interferon-alpha-2C (rIFNa2C)
Number of subjects: 40
Study 2830688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30474306 — intervention group
Group type: EXPERIMENTAL
Intervention: Real PBM (Photobiomodulation)
Number of subjects: 30
Study 30474306 — intervention group
Group type: COMPARATOR
Intervention: Sham PBM (Control)
Number of subjects: 30
Study 25264016 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland mobilization and exercises
Number of subjects: 60
Study 25264016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization and exercises
Number of subjects: 60
Study 25264016 — intervention group
Group type: COMPARATOR
Intervention: Exercises only
Number of subjects: 60
Study 23834538 — intervention group
Group type: COMPARATOR
Intervention: Upper Body Compression Garments (UBCG)
Number of subjects: 7
Study 23834538 — intervention group
Group type: COMPARATOR
Intervention: Control (no shirt or sports training bra)
Number of subjects: 7
Study 21849980 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation (TMS) at 10 Hz, specific details on dosage and duration not available.
Number of subjects: 39
Study 17912747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for 3 months
Number of subjects: 21
Study 17912747 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study 16504481 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 79
Study 16504481 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 79
Study 12687650 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR(C677T) genotype CC
Number of subjects: 2788
Study 12687650 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR(C677T) genotype CT
Number of subjects: 2788
Study 12687650 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR(C677T) genotype TT
Number of subjects: 2788
Study 12687650 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2788
Study 12687650 — intervention group
Group type: COMPARATOR
Intervention: Men compared to women
Number of subjects: 2788
Study 12742280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (25 mg/h for 1 h, then 50 mg/h for 23 to 47 h)
Number of subjects: 193
Study 12742280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 12742280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 193
Study 10797113 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) program
Number of subjects: 13
Study 9031709 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha brainwave training
Number of subjects: 20
Study 9031709 — intervention group
Group type: COMPARATOR
Intervention: Beta (mock) brainwave training
Number of subjects: 20
Study 1734558 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 18
Study 1734558 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feeding (1-hourly, 2-hourly, 3-hourly)
Number of subjects: 18
Study 6143868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus seven monthly HBIg injections
Number of subjects: 140
Study 6143868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus one HBIg injection at birth
Number of subjects: 140
Study 6143868 — intervention group
Group type: EXPERIMENTAL
Intervention: Only the vaccine at months 0, 1, 2, and 6
Number of subjects: 140
Study 6143868 — intervention group
Group type: COMPARATOR
Intervention: Placebos for both vaccine and HBIg
Number of subjects: 140
Study 3525266 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 39
Study 3525266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive conventional insulin therapy (ICT)
Number of subjects: 39
Study 3525266 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 39
Study 3525266 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT
Number of subjects: 39
Study 30810465 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model for predicting recurrent urinary tract infection associated vesicoureteral reflux
Number of subjects: 500
Study 30810465 — intervention group
Group type: COMPARATOR
Intervention: Voiding cystourethrogram
Number of subjects: 500
Study 29031905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin, 2mg daily for six months
Number of subjects: 50
Study 29031905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29031905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 50
Study 25517477 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis view
Number of subjects: 28
Study 25517477 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis view for subclavian
Number of subjects: 28
Study 25517477 — intervention group
Group type: COMPARATOR
Intervention: Short-axis view
Number of subjects: 28
Study 23861293 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/wk aerobic exercise for 4 months
Number of subjects: 141
Study 23861293 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 141
Study 21223629 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 59
Study 21223629 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus remifentanil
Number of subjects: 59
Study 21223629 — intervention group
Group type: COMPARATOR
Intervention: Sedated patients (midazolam or midazolam plus remifentanil)
Number of subjects: 59
Study 19916292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-catgut implantation (once every two weeks for the first 6 treatments, then once a month for 1 year)
Number of subjects: 68
Study 19916292 — intervention group
Group type: COMPARATOR
Intervention: Massage (20 mm, once daily for 1 year)
Number of subjects: 68
Study 16491584 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air breathing during tilt
Number of subjects: 30
Study 16491584 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% inhaled CO2 during tilt
Number of subjects: 30
Study 15270743 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with lansoprazole plus amoxicillin and tinidazole
Number of subjects: 43
Study 15270743 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with amoxicillin and tinidazole
Number of subjects: 43
Study 15270743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 43
Study 15270743 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive children
Number of subjects: 43
Study 15270743 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative children
Number of subjects: 43
Study 11375363 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-contact casts (TCC)
Number of subjects: 63
Study 11375363 — intervention group
Group type: COMPARATOR
Intervention: Removable cast walkers (RCW)
Number of subjects: 63
Study 11375363 — intervention group
Group type: COMPARATOR
Intervention: Half-shoes
Number of subjects: 63
Study 8995552 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/m2 rhTNF‐alpha intraperitoneally after drainage of fluid
Number of subjects: 39
Study 8995552 — intervention group
Group type: COMPARATOR
Intervention: Drainage alone
Number of subjects: 39
Study 8353072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, adriamycin 50 mg/m2, ifosfamide 5 G/m2) for 6 cycles at monthly intervals
Number of subjects: 99
Study 8353072 — intervention group
Group type: COMPARATOR
Intervention: Half dose chemotherapy (cyclophosphamide 300 mg/m2, carboplatin 150 mg/m2, adriamycin 25 mg/m2, ifosfamide 2.5 G/m2) for 12 cycles at monthly intervals
Number of subjects: 99
Study 8353072 — intervention group
Group type: COMPARATOR
Intervention: Half dose chemotherapy (300 mg/m2 cyclophosphamide and 150 mg/m2 carboplatin) for 12 cycles
Number of subjects: 99
Study 8353072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose chemotherapy (600 mg/m2 cyclophosphamide and 300 mg/m2 carboplatin) for 6 cycles
Number of subjects: 99
Study 8353072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both standard and low dose cycles of chemotherapy
Number of subjects: 99
Study 3301453 — intervention group
Group type: EXPERIMENTAL
Intervention: Epomediol (200 mg three times daily for 30 days)
Number of subjects: 519
Study 3301453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 29104179 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month dual antiplatelet therapy (DAPT)
Number of subjects: 1368
Study 29104179 — intervention group
Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 1368
Study 29104179 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month DAPT
Number of subjects: 1368
Study 28426355 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus CM (voucher-based contingency management)
Number of subjects: 92
Study 28426355 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 92
Study 25692915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660
Study 25692915 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660
Study 25692915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660
Study 25692915 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 660
Study 23746564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate loading (300 mg∙kg⁻¹)
Number of subjects: 11
Study 23746564 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 11
Study 21344002 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% PRO2000/5 microbicide gel
Number of subjects: 250
Study 18267977 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intravenous treatment (3 days of intravenous ceftriaxone followed by 5 days of oral antibiotics)
Number of subjects: 383
Study 18267977 — intervention group
Group type: COMPARATOR
Intervention: Long intravenous treatment (8 days of intravenous ceftriaxone)
Number of subjects: 383
Study 16584432 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT apheresis PLTs
Number of subjects: 2237
Study 16584432 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD treatment
Number of subjects: 2237
Study 16584432 — intervention group
Group type: COMPARATOR
Intervention: Untreated apheresis PLTs
Number of subjects: 2237
Study 14638556 — intervention group
Group type: EXPERIMENTAL
Intervention: Always active
Number of subjects: 229
Study 14638556 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistently active
Number of subjects: 229
Study 14638556 — intervention group
Group type: EXPERIMENTAL
Intervention: Always inactive
Number of subjects: 229
Study 11096148 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous epoetin beta (n=118)
Number of subjects: 158
Study 11096148 — intervention group
Group type: COMPARATOR
Intervention: Two or three times weekly subcutaneous epoetin beta (control group, n=40)
Number of subjects: 158
Study 11096148 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous epoetin beta
Number of subjects: 158
Study 11096148 — intervention group
Group type: COMPARATOR
Intervention: Two or three times weekly subcutaneous epoetin beta (control group)
Number of subjects: 158
Study 9263161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestructured pain behavior assessment in Study 2
Number of subjects: 45
Study 9263161 — intervention group
Group type: COMPARATOR
Intervention: Descriptive assessments of behavior in Study 1
Number of subjects: 45
Study 8323238 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 12 hours
Number of subjects: 60
Study 8323238 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 24 hours
Number of subjects: 60
Study 8323238 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 48 hours
Number of subjects: 60
Study 8323238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suction drainage)
Number of subjects: 60
Study 3092084 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 12
Study 3092084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31460597 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion program (intervention group)
Number of subjects: 109
Study 31460597 — intervention group
Group type: COMPARATOR
Intervention: Usual care from bariatric clinic staff (control group)
Number of subjects: 109
Study 29268886 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched dual antiplatelet therapy (DAPT)
Number of subjects: 645
Study 29268886 — intervention group
Group type: COMPARATOR
Intervention: Unchanged dual antiplatelet therapy (DAPT)
Number of subjects: 645
Study 25844616 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical epidermal growth factor (EGF) serum applied twice daily for 12 weeks
Number of subjects: 18
Study 23129056 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback (BIO)
Number of subjects: 18
Study 23129056 — intervention group
Group type: COMPARATOR
Intervention: Comparative group (COM)
Number of subjects: 18
Study 21813548 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI
Number of subjects: 508
Study 21813548 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAI
Number of subjects: 508
Study 21813548 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28
Number of subjects: 508
Study 21813548 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28-CRP
Number of subjects: 508
Study 21813548 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR/EULAR remission criteria
Number of subjects: 508
Study 21813548 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Estimating Equations analyses
Number of subjects: 508
Study 19003590 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective photodynamic therapy (PDT) using an optic fiber with an 810‐nm diode laser after indocyanine green (ICG) application
Number of subjects: 5
Study 16442904 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided strategy
Number of subjects: 1222
Study 16442904 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided strategy (direct current cardioversion)
Number of subjects: 1222
Study 16442904 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 1222
Study 16442904 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (direct current cardioversion)
Number of subjects: 1222
Study 15215810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment combined with streptokinase
Number of subjects: 74
Study 15215810 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase alone
Number of subjects: 74
Study 10842419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 400 mg of vitamin E and 500 mg of vitamin C
Number of subjects: 22
Study 10842419 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 22
Study 9219199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg‐1)
Number of subjects: 6
Study 9219199 — intervention group
Group type: COMPARATOR
Intervention: Breathing 100% O2
Number of subjects: 6
Study 9219199 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study 8378411 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (up to 75 mg/d)
Number of subjects: 127
Study 8378411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 3010516 — intervention group
Group type: EXPERIMENTAL
Intervention: LAV enzyme immunoassay (EIA)
Number of subjects: 1406
Study 3010516 — intervention group
Group type: COMPARATOR
Intervention: HTLV-III EIA
Number of subjects: 1406
Study 3010516 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot
Number of subjects: 1406
Study 3010516 — intervention group
Group type: EXPERIMENTAL
Intervention: LAV EIA and HTLV-III EIA
Number of subjects: 1406
Study 3010516 — intervention group
Group type: EXPERIMENTAL
Intervention: LAV EIA
Number of subjects: 1406
Study 29494784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) intervention
Number of subjects: 107
Study 29494784 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 107
Study 27409565 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 2283
Study 27409565 — intervention group
Group type: COMPARATOR
Intervention: ORBIT score
Number of subjects: 2283
Study 25336079 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised mask use
Number of subjects: 164
Study 25336079 — intervention group
Group type: COMPARATOR
Intervention: No supervised mask use (control)
Number of subjects: 164
Study 22471126 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular stimulator in the cavum concha for 30 min, once daily for 3 months
Number of subjects: 45